List view / Grid view
The new centre will serve as one of the world’s leading institutes for conducting and coordinating research about cannabinoids, endocannabinoids and medical Cannabis. In addition, it will promote collaboration and disseminate information.
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
People with certain forms of early-onset Parkinson’s disease could potentially benefit from taking a medication used to treat certain forms of cancer.
Charles River Laboratories today announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease...
A new study has identified a previously undescribed role for a type of unconventional T cell with the potential to be used in the development of new therapies for infection and cancer.
Cannabidiol shown to affect emotion and emotional memory
Included in this issue: Importance of building patient trust; Vaccines & Immunology; Oncology; Assays; Biomarkers; and Antibodies...
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
Believed by many to be a relic of past centuries, tuberculosis (TB) causes more deaths than any other infectious disease including HIV/AIDs. In 2015 there were an estimated 10.4 million new cases of TB and 1.4 million deaths from the disease.
Early warning signs of Huntington’s disease have been uncovered in sheep carrying the human HD mutation, leading the way for new insight into this devastating illness, a new study has found.
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
A team of scientists from Austria, Australia, Denmark, England and the Czech Republic, led by Christian Gruber from the MedUni Vienna's Institute of Pharmacology, managed to isolate a neuropeptide from ants that is very similar to the human love hormone oxytocin, and the closely related hormone vasopressin.
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
